Efficacy and safety of deferasirox an oral iron chelator in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

摘要

Objective:Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20–30 mg/kg/d reduces iron burden, depending on transfusional iron intake.